Deekshith Pinto15 May 2024, 10:59
The biopharmaceutical industry experiences a surge in mergers and acquisitions, with GlobalData reporting a significant increase in deal value. Big pharma companies drive this resurgence, focusing on specific drug classes like antibody-drug conjugates and radiopharmaceuticals. Notable acquisitions include Novo Nordisk's purchase of Catalent and Gilead Sciences' acquisition of CymaBay Therapeutics.